Introduction {#s1}
============

Acute myeloid leukemia (AML), the commonest acute leukemia type affecting adult individuals, results from a fast clonal expansion of cancerous myeloblasts ([@B1], [@B2]). AML has a complex and heterogeneous nature ([@B3]). Thus, it shows variable outcomes in affected individuals upon administration of current treatments. Cytotoxic chemotherapeutics are considered the mainstay therapeutic option for AML ([@B4], [@B5]). Meanwhile, allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides potent antileukemic effects and potential cure in high-risk patients ([@B6], [@B7]). In AML cases, prognosis is associated with multiple intrinsic parameters such as cytogenetic and genetic modifications. For example, NPM1, CEBPA, FLT3, IDH1, IDH2, and TET2 mutations show associations with patient outcome, and are used for AML prognosis ([@B8]--[@B10]). Although leukemogenesis is mechanistically well-understood, most AML cases remain uncured. Indeed, no currently available classification system is completely accurate. This suggests an urgent need for identifying new prognostic markers to further ameliorate AML stratification and select rational treatment options.

MicroRNAs (miRNAs) specifically bind mRNA targets and reduce the expression of encoded proteins by translation inhibition ([@B11]). Dysregulated miRNAs in AML affects cell growth and hematopoietic differentiation ([@B12], [@B13]). Furthermore, aberrant expression of miRNAs is related to patient outcome ([@B14]). For instance, elevated miR-181a content predicts favorable outcome in AML with normal cytogenetic features ([@B15]). Patients expressing elevated miR-212 amounts tend to show longer survival in all cytogenetic subtypes ([@B16]). Meanwhile, overexpression of miR-3151 is related to decreased overall and disease-free survival in cytogenetically normal AML ([@B17]). Moreover, combination of miR-3151 with the associated host gene BAALC is more efficient in predicting worse outcome. However, most published reports did not distinguish the effects of chemotherapeutics and allo-HSCT on treatment outcome. It is generally accepted that a marker\'s value in AML prognosis depends on the therapeutic method administered. Thus, miRNAs could show distinct prognostic values between chemotherapy and allo-HSCT treatment.

Here, we performed genome-wide screening to identify miRNAs with significant prognostic values in AML cases administered chemotherapeutics. We identified miR-340 as a prognostic factor independently of reported clinico-molecular predictive factors in AML. In addition, whether all-HCST overcomes the adverse prognostic impact of miR-340 expression was assessed. To assess molecular mechanisms, the expression levels of genes and miRNAs throughout the genome were determined.

Methods {#s2}
=======

Patients
--------

All the 162 cases assessed were newly diagnosed AML (non-M3 FAB subtypes) based on the WHO classification. RNA-Seq data for the above AML cases were provided by The Cancer Genome Atlas (Project ID: TCGA-LAML) ([@B18]). These AML cases were included in a single-institution tissue banking protocol that had approval from the human studies committee at Washington University (WU HSC \#01-1014). All samples were collected from patients with previously untreated *de novo* AML. MicroRNA and mRNA levels were determined before treatment. The risk classification of AML is based on the NCCN recommendation which includes cytogenetics as well as gene mutational status. Patient treatment followed the NCCN guidelines. Among the 162 cases, 148 (91.4%) received standard induction chemotherapy (3 and 7 days of anthracycline and cytarabine, respectively); the remaining 14 patients received decitabine or azacitidine. Patients with unfavorable risk underwent allo-HSCT if medically suitable for transplantation and there was a matched donor. Some cases with intermediate risk were also administered allo-HSCT during the disease course. A total of 90 cases were solely administered chemotherapy, while 72 also underwent allo-HSCT. Clinical data, such as treatment approach and outcomes, can be found on the TCGA website ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

Gene-Expression Profiling
-------------------------

One hundred and fifty-five of the 162 cases were assessed for both miRNA and mRNA expression levels. Their specimens were employed to identify genes associated with miR-340 expression. In mRNA-seq, genes showing expression levels equal or inferior to a noise threshold of RPKM (Reads per kilobase per million mapped reads) in ≥75% of specimens were excluded. In miRNA-seq, RPM (Reads per million reads) was employed for normalization. Data underwent log2 transformation pre-analysis. The mRNA levels were compared between the high and low miRNA groups, with a univariate significance level at 0.005 to identify differentially expressed genes (DEGs). Then, hierarchical clustering using the multiple experiment viewer (MeV) 4.9.0 software was carried out to order gene rows; miRBase Targets V7 and Targetscan Release 7.1 were used for predicting microRNA targets. Gene Ontology enrichment was performed of genes associated with miR-340 using the Database for Annotation, Visualization, and Integrated Discovery (DAVID).

Statistical Analysis
--------------------

Baseline features were compared between the high and low miRNA groups. Median levels of miR-340 were employed to identify patients with low and high miRNA levels. The miR-340 median values in the chemotherapy and allo-HSCT groups were 82.1 (13.2--227.5) and 75.0 (18.9--286.1), respectively. The Mann-Whitney *U*-test was employed to assess associations of two continuous variables. Fisher\'s exact test or the chi-square test was employed for categorical variables. Overall survival (OS) was defined as time between case enrolment and death, censoring live cases at final follow-up. Event-free survival (EFS) was defined as time between case enrolment and induction failure, recurrence, or death. Estimated OS and EFS distributions were determined by Kaplan-Meier curves, with the log-rank test carried out for comparing survival data.

The univariate Cox proportional hazards model was employed for evaluating associations of 340 expression with OS and EFS. The multivariate Cox proportional hazards model was used for identifying factors that affect survival. The factors assessed for model inclusion comprised miR-340 expression amounts; FLT3-ITD, NPM1, DNMT3A, RUNX1, TP53, TET2, MLL-PTD, IDH1/IDH2, and NRAS/KRAS mutation statuses; age; karyotype; and WBC involvement. Parameters with *p* = 0.10 in univariate analysis were further assessed by multivariate analysis (backward selection), in which *p* \< 0.05 indicated significance. R v3.1.5, GraphPad Prism and SPSS were employed for data analysis, and *P* \< 0.05 indicated statistically significant differences.

Results {#s3}
=======

Associations of miR-340 Levels With Clinico-Molecular Features
--------------------------------------------------------------

The chemotherapy and allo-HSCT groups were each subdivided into two according to median amounts of miRNAs, respectively. [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} summarize the associations of clinico-genetic features with miR-340 levels. In the chemotherapy group, cases with low miR-340 levels showed a higher rate of first relapse or death within 1 year after enrolment in comparison with those expressing high miR-340 amounts (82.2 vs. 55.6%, *P* = 0.012). There were no significant associations of other miR-340 expression distributions with clinical features. The above findings suggested that miR-340 expression may predict prognosis independently from known molecular features.

###### 

Comparison of clinical characteristics with miR-340 expression in AML patients.

  **Characteristic**                                **Chemotherapy group**   **Allo-HSCT group**                                                   
  ------------------------------------------------- ------------------------ --------------------- ------- ------------------- ------------------- -------
  Age/years, median                                 66 (22--81)              66 (31--88)           0.913   45.5 (21--72)       55.5 (18--65)       0.022
  Age group/*n* (%)                                                                                0.652                                           0.188
    \<60 years                                      16 (35.6)                13 (28.9)                     29 (80.6)           23 (63.9)           
    ≥60 years                                       29 (64.4)                32 (71.1)                     7 (19.4)            13 (36.1)           
  Gender/*n* (%)                                                                                   0.137                                           1.000
    Male                                            29 (64.4)                21 (46.7)                     21 (55.6)           21 (58.3)           
    Female                                          16 (35.6)                24 (53.3)                     16 (44.4)           15 (41.7)           
  WBC/ ×10^9^/L, median                             16 (1.5--298.4)          15.2 (0.7--297.4)     0.840   31.6 (1.2--223.8)   23.6 (0.6--118.8)   0.209
  BM blast/%, median                                67 (30--98)              76 (32--99)           0.056   70.5 (34--91)       70 (30--100)        0.191
  PB blast/%, median                                37 (0--97)               23 (0--98)            0.929   53 (0--96)          37 (0--91)          0.054
  FAB subtypes/*n* (%)                                                                                                                             
    M0                                              3 (6.7)                  5 (11.1)              0.549   3 (8.3)             6 (16.7)            0.478
    M1                                              9 (20.0)                 11 (24.4)             0.800   15 (41.7)           8 (22.2)            0.129
    M2                                              14 (31.1)                7 (15.6)              0.134   12 (33.3)           7 (19.4)            0.285
    M4                                              13 (28.9)                11 (24.4)             0.812   5 (13.9)            9 (25.0)            0.372
    M5                                              4 (8.9)                  9 ([@B20])            0.230   0                   4 (11.1)            0.115
    M6                                              0 (0)                    1 (2.2)               1.000   0                   1 (2.8)             1.000
    M7                                              1 (2.2)                  1 (2.2)               1.000   0                   1 (2.8)             1.000
  Others                                            1 (2.2)                  0 (0)                 1.000   1 (2.2)             0                   1.000
  Karyotype/*n* (%)                                                                                                                                
    Normal                                          21 (46.7)                23 (51.1)             0.833   13 (36.1)           21 (58.3)           0.098
    Complex                                         6 (13.3)                 6 (13.3)              1.000   6 (16.7)            6 (16.7)            1.000
    8 Trisomy                                       2 (4.4)                  0 (0)                 0.494   0                   4 (11.1)            0.115
    CBFβ-MYH11                                      5 (11.1)                 2 (4.4)               0.434   5 (13.9)            0                   0.054
    11q23/MLL                                       1 (2.2)                  3 (6.7)               0.616   0                   3 (8.3)             0.239
    −7/7q-                                          1 (2.2)                  2 (4.4)               1.000   3 (8.3)             0                   0.239
    BCR-ABL1                                        1 (2.2)                  0                     1.000   2 (5.6)             0                   0.493
    RUNX1-RUNX1T                                    5 (11.1)                 1 (2.2)               0.203   1 (2.8)             0                   1.000
    Others                                          3 (6.7)                  8 (17.8)              0.197   6 (16.7)            2 (5.6)             0.260
  Risk/*n* (%)[^a^](#TN1){ref-type="table-fn"}                                                                                                     
    Good                                            10 (22.2)                3 (6.7)               0.069   6 (16.7)            0                   0.025
    Intermediate                                    24 (53.3)                26 (57.8)             0.832   15 (41.7)           26 (72.2)           0.017
    Poor                                            10(22.2)                 15 (33.3)             0.233   14 (38.9)           10 (37.8)           0.454
    Others                                          1 (2.2)                  1 (2.2)               1.000   1 (2.8)             0(0)                1.000
  Induction regimen                                                                                1.000                                           1.000
    7 + 3                                           38                       38                            35                  36                  
    Decitabine                                      6                        7                             1                   0                   
    Azacitidine                                     1                        0                             0                   0                   
  Donor types                                                                                                                                      0.021
    MUD                                             --                       --                            23(63.9)            15(41.7)            
    Sibling                                         --                       --                            11(30.6)            21(58.3)            
    Haploidentical                                  --                       --                            2(5.5)              0(0)                
  Relapse/*n* (%)[^b^](#TN2){ref-type="table-fn"}                                                  0.012                                           0.48
    Yes                                             25 (55.6)                37 (82.2)                     16 (44.4)           20 (55.6)           
    No                                              20 (44.4)                8 (17.8)                      20 (55.6)           16 (44.4)           

Mann-Whitney test was used for continuous variables. Chi-square tests were used for categorical variables.

WBC, white blood cell; BM, bone marrow; PB, peripheral blood; FAB, French-American-British classification; MUD, Matched unrelated donor.

The risk classification of AML is based on NCCN recommendation which includes cytogenetics as well as gene mutational status.

*First Relapse or death within one year*.

###### 

Comparison of molecular characteristics with miR-340 expression in AML patients.

  **Characteristic**   **Chemotherapy group**   **Allo-HSCT group**                                   
  -------------------- ------------------------ --------------------- ------- ----------- ----------- -------
  FLT3-ITD/*n* (%)                                                    0.409                           0.155
    Presence           6 (13.3)                 10 (22.2)                     5 (13.9)    11 (30.6)   
    Absence            39 (86.7)                35 (77.8)                     31 (86.1)   25 (69.4)   
  NPM1/*n* (%)                                                        0.175                           0.003
    Mutation           11 (24.4)                18 (40.0)                     4 (11.1)    16 (44.4)   
    Wild type          34 (75.6)                27 (60.0)                     32 (88.9)   20 (55.6)   
  CEBPA/*n* (%)                                                                                       
    Single mutation    1 (2.2)                  2 (4.4)               1.000   4 (11.1)    1 (2.8)     0.357
    Double mutation    0                        0                             3 (8.3)     0           0.239
    Wild type          44 (97.8)                43 (95.6)             1.000   29 (80.6)   35 (97.2)   0.055
  DNMT3A/*n* (%)                                                      0.157                           0.055
    Mutation           9 (20.0)                 16 (35.6)                     5 (13.9)    13 (36.1)   
    Wild type          36 (80.0)                29 (64.4)                     31 (86.1)   23 (63.9)   
  IDH1/IDH2/*n* (%)                                                   0.409                           1.000
    Mutation           10 (22.2)                6 (13.3)                      9 (25.0)    9 (25.0)    1.000
    Wild type          35 (77.8)                41 (86.7)                     27 (75.0)   27 (75.0)   
  RUNX1/*n* (%)                                                       0.714                           0.710
    Mutation           5 (1.1)                  3 (6.7)                       3 (8.3)     5 (13.9)    
    Wild type          40 (88.9)                42 (93.3)                     33 (91.7)   31 (86.1)   
  MLL-PTD/*n* (%)                                                     1.000                           0.614
    Presence           3 (6.7)                  2 (4.4)                       1 (2.8)     3 (8.3)     
    Absence            42 (93.3)                43 (95.6)                     35 (97.2)   33 (91.7)   
  NRAS/KRAS/*n* (%)                                                   1.000                           0.429
    Mutation           7 (15.6)                 6 (13.3)                      5 (11.1)    2 (2.8)     
    Wild type          38 (84.4)                39 (86.7)                     31 (88.9)   34 (97.2)   
  TET2/*n* (%)                                                        0.758                           1.000
    Mutation           7 (15.6)                 5 (11.1)                      2 (5.6)     2 (5.6)     
    Wild type          38 (84.4)                40 (88.9)                     33 (94.4)   34 (94.4)   
  TP53/*n* (%)                                                        0.522                           0.614
    Mutation           7 (15.6)                 4 (8.9)                       1 (2.8)     3 (8.3)     
    Wild type          38 (84.4)                41 (91.1)                     35 (97.2)   33 (91.7)   

*Chi-square tests were used for categorical variables*.

Prognostic Value of miR-340 in Cases Administered Chemotherapy or Allo-HSCT
---------------------------------------------------------------------------

To obtain prognostic markers for refining AML stratification, a genome-wide screen of miRNAs in AML patients was carried out; miR-340 was detected as a novel molecule predicting prognosis in AML cases treated by chemotherapy. In the chemotherapy group, low miR-340 expressers showed starkly reduced OS (*P* = 0.0005) and EFS (*P* = 0.0005) in comparison with high expressers ([Figure 1A](#F1){ref-type="fig"}). Notably, 5 year OS rates were 35.6 and 5.4% in the high and low miR-340 expression groups, respectively. However, miR-340 levels were not associated with patient outcome in AML after allo-HCST ([Figure 1B](#F1){ref-type="fig"}). The above findings indicated that low miR-340 was an unfavorable prognostic factor in AML cases administered chemotherapy.

![Kaplan-Meier survival curves based on miR-340 expression. **(A)** Cases highly expressing miR-340 showed markedly prolonged OS and EFS in the chemotherapy group (*n* = 90). **(B)** Effects of miR-340 levels on OS and EFS in cases administered allo-HSCT (*n* = 72).](fonc-09-01058-g0001){#F1}

MiR-340 Is Independently Associated With Clinical Outcome in Patients With AML
------------------------------------------------------------------------------

To assess whether miR-340 levels independently predict survival in AML, univariable and multivariate cox analyses were carried out. Univariate analysis ([Table 3](#T3){ref-type="table"}) revealed low miR-340 had a significant association with reduced OS (HR = 2.393, *P* = 0.001) and EFS (HR = 2.383, *P* = 0.001) in patients treated by chemotherapy. In multivariate analysis, miR-340 and many known prognostic factors were evaluated ([Table 3](#T3){ref-type="table"}). Low miR-340 expression was independently predictive of reduced OS (HR = 2.07, *P* = 0.004) and EFS (HR = 1.909, *P* = 0.01) upon adjustment for age (*P* \< 0.0001) and karyotype risk (*P* \< 0.0001). In patients administered allo-HSCT, univariate analysis revealed TP53-mutant cases displayed adverse OS (*P* = 0.009); however, the miR-340 expression status was not associated with OS and EFS ([Table 4](#T4){ref-type="table"}). Multivariable analysis showed TP53 and FLT3-ITD mutations were independently predictive of reduced OS (*P* = 0.003 and *P* = 0.031, respectively). Therefore, the miR-340 expression status did not remain a survival predictor after allo-HSCT.

###### 

Univariate and multivariate analyses in patients treated with chemotherapy.

  **Variables**                               **EFS**                **OS**                          
  ------------------------------------------- ---------------------- -------- ---------------------- -------
  **Univariate analyses**                                                                            
  MiR-340 (low vs. high)                      2.383 (1.455--3.903)   0.001    2.393 (1.458--3.927)   0.001
  Age (≥60 vs. \<60)                          3.560 (1.960--6.467)   0.000    3.328 (1.838--6.024)   0.000
  Karyotype[^a^](#TN3){ref-type="table-fn"}   3.827 (2.181--6.716)   0.000    4.069 (2.309--7.170)   0.000
  WBC (≥20 vs. \<20 × 10^9^/L)                1.015 (0.633--1.627)   0.952    0.980 (0.611--1.571)   0.932
  FLT3-ITD (positive vs. negative)            1.095 (0.587--2.040)   0.776    1.049 (0.563--1.956)   0.880
  NPM1 (mutated vs. wild)                     1.050 (0.633--1.741)   0.850    0.965 (0.582--1.599)   0.890
  DNMT3A (mutated vs. wild)                   1.301 (0.774--2.185)   0.320    1.299 (0.775--2.179)   0.321
  RUNX1 (mutated vs. wild)                    1.502 (0.717--3.147)   0.281    1.591 (0.759--3.335)   0.219
  TP53 (mutated vs. wild)                     3.011 (1.539--5.892)   0.001    2.898 (1.487--5.649)   0.002
  TET2 (mutated vs. wild)                     0.778 (0.372--1.625)   0.504    0.686 (0.328--1.434)   0.316
  MLL-PTD (mutated vs. wild)                  0.891 (0.324--2.445)   0.822    0.945 (0.344--2.596)   0.913
  IDH1/IDH2 (mutated vs. wild)                0.973 (0.271--1.273)   0.926    0.988 (0.550--1.777)   0.969
  NRAS/KRAS (mutated vs. wild)                1.214 (0.637--2.314)   0.556    1.228 (0.644--2.340)   0.532
  **Multivariate analyses**                                                                          
  MiR-340 (low vs. high)                      1.909 (1.164--3.132)   0.010    2.070 (1.260--3.400)   0.004
  Age (≥60 vs. \<60)                          3.555 (1.916--6.598)   0.000    3.103 (1.672--5.758)   0.000
  Karyotype[^a^](#TN3){ref-type="table-fn"}   3.925 (2.151--7.161)   0.000    3.762 (2.088--6.779)   0.000
  WBC (≥20 vs. \<20 × 10^9^/L)                1.670 (0.998--2.794)   0.051    1.678 (0.997--2.822)   0.051
  DNMT3 (mutated vs. wild)                    1.677 (0.968--2.905)   0.065    --                     --

EFS, Event-free survival; OS, Overall survival; WBC, white blood cell.

*Unfavorable cytogenetics vs. others*.

###### 

Univariate and multivariate analyses in patients treated with allo-HSCT.

  **Variables**                                      **EFS**                 **OS**                           
  -------------------------------------------------- ----------------------- -------- ----------------------- -------
  **Univariate analyses**                                                                                     
  MiR-340 (low vs. high)                             1.627 (0.881--3.005)    0.120    1.738 (0.941--3.208)    0.077
  Age (≥60 vs. \<60)                                 0.873 (0.438--1.741)    0.700    1.190 (0.594--2.382)    0.624
  Karyotype[^a^](#TN4){ref-type="table-fn"}          1.241(0.659--2.339)     0.504    1.376 (0.731--2.591)    0.323
  WBC (≥20 vs. \<20 × 10^9^/L)                       1.089 (0.594--1.999)    0.782    0.826 (0.450--1.516)    0.537
  Remission status[^b^](#TN5){ref-type="table-fn"}   0.798 (0.381--1.670)    0.549    0.616 (0.293--1.296)    0.202
  Donor types[^c^](#TN6){ref-type="table-fn"}        0.941 (0.514--1.725)    0.845    0.713 (0.388--1.310)    0.276
  FLT3-ITD (positive vs. negative)                   1.876 (0.914--3.851)    0.086    1.973 (0.953--4.084)    0.067
  NPM1 (mutated vs. wild)                            1.007 (0.515--1.970)    0.983    1.023 (0.523--1.998)    0.948
  DNMT3A (mutated vs. wild)                          1.285 (0.655--2.520)    0.466    1.387 (0.704--2.731)    0.344
  RUNX1 (mutated vs. wild)                           1.145 (0.449--2.290)    0.777    1.579 (0.613--4.067)    0.344
  TP53 (mutated vs. wild)                            2.034 (0.718--5.760)    0.181    4.334 (1.453--12.925)   0.009
  TET2 (mutated vs. wild)                            0.526 (0.127--2.186)    0.377    0.670 (0.162--2.776)    0.581
  MLL-PTD (mutated vs. wild)                         5.775 (1.664--20.042)   0.006    2.728 (0.832--8.944)    0.098
  IDH1/IDH2 (mutated vs. wild)                       0.587 (0.271--1.273)    0.177    0.633 (0.293--1.368)    0.245
  NRAS/KRAS (mutated vs. wild)                       0.796 (0.245--2.586)    0.705    0.488 (0.150--1.587)    0.233
  **Multivariate analyses**                                                                                   
  MLL-PTD (mutated vs. wild)                         5.775 (1.664--20.042)   0.006    --                      --
  FLT3-ITD (positive vs. negative)                   --                      --       2.274 (1.080--4.788)    0.031
  TP53 (mutated vs. wild)                            --                      --       5.361 (1.746--16.454)   0.003

EFS, Event-free survival; OS, Overall survival; WBC, white blood cell.

Unfavorable cytogenetics vs. others.

CR vs. non-CR.

*Matched unrelated donor (MUD) vs. matched sibling + haploidentical donors*.

Allo-HSCT Overcomes the Adverse Prognostic Effects of Low miR-340 Expression in AML
-----------------------------------------------------------------------------------

Whether allo-HSCT overcomes the unfavorable effects of low miR-340 expression was assessed. The 162 cases were assigned to two groups based on miR-340 levels. Then, each group was further divided into the chemotherapy and allo-HSCT groups. In cases with low miR-340 expression, significantly longer OS (HR = 0.316, 95% CI 0.167--0.459, *P* \< 0.0001) and EFS (HR = 0.391, 95% CI 0.231--0.622, *P* = 0.002) were observed after allo-HSCT ([Figure 2A](#F2){ref-type="fig"}). However, there were no differences in OS (*P* = 0.060) and EFS (*P* = 0.162) between the allo-HSCT and chemotherapy groups in high miR-340 expressers ([Figure 2B](#F2){ref-type="fig"}). The above findings indicated miR-340 might constitute a novel molecule for detecting cases requiring strategies to select a rational therapeutic management.

![Allo-HSCT overcomes the adverse prognostic influence of low miR-340 expression in AML. **(A)** The 162 cases were divided into two groups according to median miR-340 levels. Kaplan-Meier survival curves for cases administered chemotherapy (*n* = 47) and allo-HSCT (*n* = 34), respectively, in the low miR-340 group. **(B)** Kaplan-Meier survival curves for cases administered chemotherapy (*n* = 43) and allo-HSCT (*n* = 8), respectively, in the high miR-340 group.](fonc-09-01058-g0002){#F2}

Biological Insights Into miR-340 Function in AML
------------------------------------------------

To gain insights into the biological functions of miR-340, gene expression signatures related to the miRNA expression were assessed in AML patients. As shown in [Figure 3](#F3){ref-type="fig"}, the expression levels of 135 genes showed significant associations with miR-340 expression, with 61 and 74 positively and negatively correlated, respectively. In this study, miR-340 expression was negatively associated with HOXA/HOXB cluster and MEIS1 amounts. The latter genes are important in AML leukemogenesis and self-renewal features in leukemic stem cells ([@B19]). We further analyzed the biological significance of these genes by separating AML cases into two groups according to median miR-340 expression. In the low miR-340 expression group, the HOXA1 (*P* = 0.0112), HOXA2 (*P* = 0.019), HOXA3 (*P* \< 0.0001), HOXA4 (*P* = 0.0005), HOXA5 (*P* \< 0.0001), HOXA6 (*P* \< 0.0001), HOXA7 (*P* \< 0.0001), HOXA9 (*P* = 0.0004), HOXA10 (*P* \< 0.0001), HOXB2 (*P* = 0.0026), HOXB3 (*P* \< 0.0001), HOXB4 (*P* \< 0.0001), HOXB6 (*P* \< 0.0001), MEIS1 (*P* = 0.0001), and PRDM16 (*P* = 0.0002) genes were all expressed at higher levels compared with high miR-340 expression group. Notably, the histone H3K4 methyltransferase PRDM16, a gene that predicts adverse outcome in AML ([@B20]), was downregulated in the high miR-340 group. Strikingly, HOXA10, HOXB2, MEIS1 and PRDM16 were identified as miR-340 targets by *in silico* prediction. These findings corroborated clinical data for AML generated by miRNA analysis.

![Heat map of the gene expression signature related to miR-340 expression in AML. Cases (columns) were ordered from left to right by increasing miR-340 levels. Genes (rows) were ordered by hierarchical cluster analysis. Blue and red reflect expression levels lower and above median values for the indicated genes, respectively; miR-340 associated genes are indicated.](fonc-09-01058-g0003){#F3}

Gene Ontology revealed that genes contributing to biological regulation, cellular and developmental processes, transcription regulation, immune system process, cell apoptosis and proliferation, myeloid cell differentiation, hematopoietic organ development, cellular response to chemical stimulus and embryonic morphogenesis were remarkably overrepresented among DEGs related to miR-340 expression ([Table 5](#T5){ref-type="table"}).

###### 

Gene ontology terms of biological processes in the miR-340 associated expression profile.

  **GO ID**    **GO Terms**                                          **Percentage of members of the GO term present in the miR-363 profile**   ***P*-value**
  ------------ ----------------------------------------------------- ------------------------------------------------------------------------- ---------------
  GO:0065007   Biological regulation                                 71.8                                                                      0.001
  GO:0050794   Regulation of cellular process                        65.3                                                                      0.004
  GO:0032501   Multicellular organismal process                      55.6                                                                      \<0.001
  GO:0032502   Developmental process                                 46.0                                                                      \<0.001
  GO:0048731   System development                                    38.7                                                                      \<0.001
  GO:0006355   Regulation of transcription, DNA-templated            24.2                                                                      0.007
  GO:0070887   Cellular response to chemical stimulus                20.2                                                                      0.043
  GO:0002376   Immune system process                                 19.4                                                                      0.036
  GO:0042981   Regulation of apoptotic process                       13.7                                                                      0.015
  GO:0042127   Regulation of cell proliferation                      13.7                                                                      0.036
  GO:0048598   Embryonic morphogenesis                               12.9                                                                      \<0.001
  GO:0009790   Embryo development                                    12.9                                                                      0.001
  GO:0048534   Hematopoietic or lymphoid organ development           9.7                                                                       0.011
  GO:0002520   Immune system development                             9.7                                                                       0.015
  GO:0045637   Regulation of myeloid cell differentiation            4.8                                                                       0.007
  GO:0045638   Negative regulation of myeloid cell differentiation   4.0                                                                       0.029

*GO, Gene Ontology*.

Discussion {#s4}
==========

Identifying new prognostic markers is of great importance in adult AML, because currently available molecular stratification approaches do not completely capture the heterogeneity of such cases ([@B21]--[@B23]). The significance of miRNAs as predictive biomarkers in AML patients remains mostly unclear. The present work demonstrated that miR-340 independently predicted prognosis of AML patients administered chemotherapy, providing an important tool for risk-stratifying AML cases. Of greater importance, allo-HSCT overcame miR-340-associated unfavorable outcomes.

Aberrant miRNA expression has a potential prognostic value in AML ([@B24]). High amounts of miR-155 ([@B25]), miR-196b ([@B26]), miR-362 ([@B27]), miR-363 ([@B22]), and miR-551b ([@B28]) show associations with adverse clinical outcomes. Conversely, elevated amounts of miR-9^\*^ ([@B29]), miR-34a ([@B30]), miR-181a ([@B15]), miR-193b ([@B31]), miR-212 ([@B16]) and miR-425 ([@B14]) predict favorable prognosis. As shown above, miR-340 expression independently predicted prognosis in a heterogeneous population of AML cases treated by chemotherapy. Low miR-340 amounts showed associations with reduced survival and risk of disease relapse or death. These findings suggest that miR-340 could enhance the prognostic value of currently known biomarkers in AML. Meanwhile, identifying low miR-340 expression as an adverse prognostic factor could guide intervention with synthetic miR-340 molecules. These findings indicate miR-340 functions independently to impact treatment outcome, and may drive leukemogenesis.

Routine therapeutic approaches after AML remission include conventional chemotherapy and allo-HCST ([@B32]). However, prognostic biomarkers efficiently guiding treatment selection are lacking. As demonstrated above, low miR-340 expressers treated by allo-HSCT had remarkably prolonged OS and EFS compared with the chemotherapy group. Notably, no benefit of allo-HSCT was found in cases highly expressing miR-340. The above results suggest that allo-HSCT as first line treatment might be of limited value in cases highly expressing miR-340. Thus, miR-340 levels might help identify individuals requiring strategies for selecting the most suitable therapeutic option between chemotherapy and allo-HCST. Low miR-340 expressing cases may be strongly considered for early allo-HSCT.

The tumor suppressor activity of miR-340 has been described in solid malignancies such as breast, colorectal and non-small cell lung cancers, as well as osteosarcoma and glioblastoma ([@B33]--[@B35]). However, miR-340\'s biological role in AML cells is largely undefined. As shown above, miR-340 levels were negatively correlated with HOXA/HOXB cluster and MEIS1 amounts. HOX genes are essential regulators of hematopoietic development and stem cell self-renewal ([@B36]). Abnormal overexpression of HOXA and MEIS1 represents a known hallmark of AML ([@B19]). Furthermore, artificial overexpression of HOXA7, HOXA9, or HOXA10 in combination with MEIS1 leads to rapid onset AML in animal models ([@B37]). High expression of HOXA9 in leukemia blasts predicts adverse outcome in AML. High expression levels of HOXA10 ([@B38], [@B39]) and MEIS1 ([@B40]) genes also predict poor outcome in AML. Notably, HOXA10, HOXB2, and MEIS1 were predicted *in silico* to be miR-340 targets in this study. Although they are potential therapeutic targets, developing chemical inhibitors of transcription factor remains challenging. Targeting these genes with synthetic miR-340 compounds may be a potential therapeutic strategy. Taken together, the miR-340 associated gene signature may confirm the notion that AML features miRNA expression changes. However, the mechanisms involved in miR-340 modulation and associated effects on patient outcome in AML after treatment deserve further attention.

Conclusions {#s5}
===========

MiR-340 amounts are independently associated with treatment outcome in a highly heterogeneous population of AML patients. MiR-340 amount determination may provide a powerful tool for the identification of a patient subset with adverse outcome in AML, and might help ameliorate stratification risk and inform therapeutic decision making for AML patients. Interestingly, allo-HSCT may overcome miR-340-associated deleterious effects in AML. Therefore, miR-340 expression analysis could help identify patients requiring complex approaches in selecting the most suitable therapeutic option between chemotherapy and allo-HCST.
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AML

:   acute myeloid leukemia

Allo-HSCT

:   allogeneic hematopoietic stem cell transplantation

TCGA

:   The Cancer Genome Atlas

OS

:   overall survival

EFS

:   event-free survival.
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